Shanghai OPM Biosciences (SH:688293) Zheng Quan Zhi Xing·2025-06-05 16:18Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biomedical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2]. Group 1 - The company intends to purchase the equity from various investment partners and individuals, including PharmaLegacy Hong Kong Limited and several limited partnership investment firms [1]. - The board of directors has confirmed that the company does not fall under any prohibitive conditions outlined in Article 11 of the "Administrative Measures for the Registration of Securities Issuance by Listed Companies" [2]. - The company has conducted a thorough review and determined that there are no recent negative audit opinions or significant legal issues that would prevent the issuance of shares to specific investors [2].